Phathom Pharmaceuticals
PHAT
114 hedge funds and large institutions have $599M invested in Phathom Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 48 increasing their positions, 21 reducing their positions, and 17 closing their positions.
755% more call options, than puts
Call options by funds: $5.18M | Put options by funds: $606K
129% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 21
11% more funds holding in top 10
Funds holding in top 10: 9 → 10 (+1)
4.53% more ownership
Funds ownership: 94.74% → 99.27% (+4.5%)
6% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 17
2% more capital invested
Capital invested by funds: $588M → $599M (+$10.4M)
0% more funds holding
Funds holding: 114 → 114 (0)
Top Buyers
| 1 |
PCM
Portolan Capital Management
Boston,
Massachusetts
|
+$11.6M |
| 2 |
Jennison Associates
New York
|
+$11.4M |
| 3 |
Morgan Stanley
New York
|
+$5.41M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$4.68M |
| 5 |
CC
Checkpoint Capital
San Francisco,
California
|
+$4.43M |
Top Sellers
| 1 |
TPC
Takeda Pharmaceutical Company
Tokyo,
Japan
|
-$16.4M |
| 2 |
OCA
Octagon Capital Advisors
New York
|
-$4.83M |
| 3 |
6CM
683 Capital Management
New York
|
-$2.57M |
| 4 |
Millennium Management
New York
|
-$2.39M |
| 5 |
NM
Newtyn Management
New York
|
-$1.75M |
PHAT Hedge Fund Activity: Q2 2024 in Review
114 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q2 2024, worth a combined $599M — up 1.8% from $588M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new PHAT positions and 17 closed out — a net gain of 1 holder — while 48 added to existing stakes and 21 trimmed.
The largest buyer was Portolan Capital Management, opening a new position worth an estimated $11.6M. The largest seller was Takeda Pharmaceutical Company, cutting an estimated $16.4M.
- 114 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $599M of Phathom Pharmaceuticals stock for Q2 2024, up 1.8% quarter-over-quarter.
- 18 funds opened new Phathom Pharmaceuticals positions in Q2 2024 and 17 closed out, a net change of +1 holder.
- The largest Phathom Pharmaceuticals buyer in Q2 2024 was Portolan Capital Management, an estimated $11.6M added.
- The largest Phathom Pharmaceuticals seller in Q2 2024 was Takeda Pharmaceutical Company, an estimated $16.4M sold.
Based on aggregated 13F filings for Q2 2024.